January 2008 Br J Cardiol 2008;15:7-11
BJCardio editorial team
Two phase I studies with anacetrapib (Lancet 2007;370:1907–14), show impressive effects on raising high-density lipoprotein cholesterol (HDL-C) and lowering low-density lipoprotein (LDL-C), with no signs of any increase in blood pressure. The authors, from Merck, US, conclude: “Anacetrapib seems to exhibit HDL-C increases greater than those seen with other investigational drugs in this class and LDL-C-lowering effects similar to statins. Despite greater lipid-altering effects relative to other members of this class, anacetrapib seems not to increase blood pressure, suggesting that potent CETP inhibition by itself might not lead to incre
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits